- Home
- DVAX vs KZR Comparison
DVAX vs KZR Comparison
Compare DVAX & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVAX | KZR |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 29.7M |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DVAX | KZR |
|---|---|---|
| Price | $10.89 | $6.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $26.50 | $6.00 |
| AVG Volume (30 Days) | ★ 1.7M | 36.6K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,514,000.00 | N/A |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $3.53 |
| 52 Week High | $14.63 | $7.25 |
Technical Indicators
Market Signals| Indicator | DVAX | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 64.69 |
| Support Level | $10.79 | $6.13 |
| Resistance Level | $11.10 | $6.29 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 30.00 | 80.00 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.